Gout researchers are not using OMERACT recommended trial outcomes. Acute gout trials reported an average of 2.9 out of the 5 proposed OMERACT outcome domains, while 2.5 of the 9 preliminary domains were included in chronic gout trials. Research also showed a preference for non-patient reported outcomes.
To truly understand burden of disease and treatment impact, “it is of the utmost importance to measure of patient-related domains,” said the researchers including Rachelle Buchbinder from RNSH in Sydney.